The groups will conduct a study evaluating the benefits of targeted next-generation sequencing in the diagnosis and care of infants with genetic disorders.
The Post and Courier discusses a South Carolina court's decision in the Williams v Quest case.
One woman affected by Ireland's cervical cancer scandal has settled with the Irish health service and US-based Quest Diagnostics.
Though the South Carolina Supreme Court said Quest was a healthcare provider, Williams can try to keep her case alive by arguing she's alleging ordinary negligence.
The court's ruling that Quest was acting as a licensed healthcare provider could affect the statute of limitations in the suit.
The prospective analysis suggests that the approach could help clinicians identify patients at risk of a stroke who could benefit from anticoagulant treatment.
The companies are accelerating the pace of an existing collaboration with the goal of detecting SMA "2+0" carrier status.
The 4,000-participant study will use a digital enrollment platform and will provide free genetic testing as well as support from doctors and genetics experts.
The court's determination is critical to deciding if Williams v Quest/Athena can advance or if it must be dismissed on statute of repose grounds.
Sensitivity problems with rapid antigen tests are also helping the more accurate rapid molecular tests gain wider acceptance, manufacturers said.
NPR reports that with medical data being big business, some companies want to get patients involved.
The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.
In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.